Polaris Partners

1366 Technologies is a manufacturer of silicon wafers used to deliver solar modules. The company's silicon wafers leverage existing billion-dollar cell and module investments, enabling businesses to get a long-term, differentiated product roadmap. It was founded in 2008 and is headquartered in Bedford, Massachusetts.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. The company’s lead products, AL001, AL101, AL002, and AL003, are currently undergoing various stages of clinical trials, with AL001 in a phase II trial for frontotemporal dementia and AL101 in phase I trials targeting multiple neurodegenerative conditions. Alector employs advanced antibody technology combined with insights from neuroimmunology and human genetics to create therapeutics that address underlying disease mechanisms. The company has established a collaboration with Adimab, which specializes in the discovery and optimization of antibody therapeutics, to enhance its research and development efforts. Alector also has several additional programs in the research and development stage, reflecting its commitment to advancing novel treatments for complex neurological disorders. Founded in 2013 and headquartered in South San Francisco, California, Alector aims to restore healthy immune function in the brain through its unique therapeutic approaches.

Iora Health is dedicated to providing possible service and care for each patient without any of the barriers or excuses that plague the current system. They’ve completely redesigned Primary Care to help patients better manage their health and navigate the health care system. Every patient gets a personal physician as well as a personal health coach who stays in close contact during and between office visits, both of whom are available by email, text, or video in addition to in-person visits. In addition, they provide educational offerings, including group visits, to help patients stay on track with their health goals.

Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions. The company was founded in 2012 and is based in Lebanon, New Hampshire.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Neuronetics, Inc. is a commercial stage medical technology company that specializes in developing non-invasive therapies for psychiatric disorders. Founded in 2003 and headquartered in Malvern, Pennsylvania, the company markets the NeuroStar Advanced Therapy System, which provides a non-invasive treatment for adults suffering from major depressive disorder. This system employs transcranial magnetic stimulation (TMS) to generate a pulsed, MRI-strength magnetic field that induces electrical currents aimed at stimulating specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team targeting psychiatrist customers, focusing on improving the quality of life for individuals with mental health challenges.

MarkMonitor, the global leader in enterprise brand protection, offers comprehensive solutions and services that safeguard brands, reputation and revenue from online risks. With end-to-end solutions that address the growing threats of online fraud, brand abuse and unauthorized channels, MarkMonitor enables a secure Internet for businesses and their customers. The company's exclusive access to data combined with its patented real-time prevention, detection and response capabilities provide wide-ranging protection to the ever-changing online risks faced by brands today.

Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

Heavy is a platform for the most sought-after news and information. Through its flagship website, Heavy.com, and Spanish-language platform, AhoraMismo.com, readers benefit from rapid, unbiased reporting to access the content they want in real time. Heavy.com was founded by entrepreneurs Simon Assaad and David Carson in 1999 as a video-focused entertainment site aimed primarily at young men. It rebooted in 2012 as a news site and today receives nearly 25 million readers a month. Assaad continues to serve as CEO. Heavy’s content is driven by data around the stories, trends and products people search for the most. The editorial team is made up of a mix of veteran reporters with independent journalists, who work on an editorial agenda built for quality, efficiency and speed. Heavy’s rapid original reporting and user-friendly formats, such as its “5 Fast Facts” posts, offer facts about trending topics in real time. Heavy has also been recognized for reporting well ahead of mainstream news sites and is often sourced in editorial reporting. AhoraMismo is a Spanish-language platform that equips U.S. Hispanics with news, information and other resources to help them navigate daily life. From entertainment and sports news to educational content on health, wellness and women’s issues, to analysis of important issues such as immigration, politics and financial planning, AhoraMismo arms its readers with tools to be more informed and improve their quality of life.

Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

eRealty.com is an online residential real estate brokerage firm that assists buyers and sellers of homes. The company was founded in 1998 and is based in Houston, Texas.

"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."